GLP-1/GIP receptor activating therapy to help adults quit smoking and lose weight
Official title: Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation
Funded at University of Southern California · NIH-11373082 · Data updated 2026-11-12
A large study will test a GLP-1/GIP receptor agonist to help adults with atherosclerotic cardiovascular disease quit smoking and manage weight.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | July 15, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $2,901,274 |
| NIH project number | 5U01DA064384-02 |
| Project ID | NIH-11373082 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 and older with ASCVD who are motivated to quit smoking and manage weight.
✕Less likely to help
People without ASCVD or those unwilling to quit smoking may see little benefit.
What this research studies
This national multi-site trial will enroll adults with ASCVD to see if a once-daily long-acting GLP-1/GIP receptor agonist can support cigarette abstinence and reduce post-cessation weight gain. Participants will be randomly assigned to receive the drug or a comparison, with follow-up to track smoking status, cravings, weight changes, and safety. The study builds on early clues that incretin-based therapies may curb nicotine intake and cravings in people who smoke. If successful, this approach could offer a new pharmacological option for those who struggle to quit and manage obesity-related risks. Participation would involve regular visits, questionnaires, and monitoring for side effects.
Why it matters
Potential benefit: If successful, the treatment could improve smoking cessation rates and help control weight, potentially reducing cardiovascular risk.
How similar studies have gone: Preliminary data suggest GLP-1/GIP therapies may reduce cravings and cigarette use, but larger treatment-seeking trials are needed.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Hendershot, Christian S — University of Southern California
- Study coordinator: Hendershot, Christian S
Related research
Other NIH-funded projects on the same topics.
-
Social stress and smoking: why disadvantaged young adults struggle to quit
This grant looks at how daily social stress affects if and when disadvantaged young adults who smoke can quit and stay quit.
-
I-STOP: a mobile health program to help people with HIV quit smoking
A smartphone-based program designed to help people with HIV quit smoking in a sustainable, affordable way.
-
Smoking cessation help for people with HIV in South Africa
A program is being tested to help people living with HIV in South Africa quit smoking in ways that fit low-resource clinics and show good value.
-
Mobile tools to understand how sleep affects quitting smoking
This project uses a smartphone to track sleep and smoking in lower-income adults trying to quit to find how sleep patterns relate to staying smoke-free.
-
Integrated approach to lung screening and quitting for African Americans
A multi-level program aims to boost LDCT lung cancer screening uptake and help African American smokers quit, with support from a comprehensive community-focused plan.
-
Peer-led smoking-cessation program for public housing residents
A peer-led program with eight group sessions plus nicotine replacement therapy is tested on adults living in public housing to help them quit smoking.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.